Mitrović, Nikola (55110096400)Nikola (55110096400)MitrovićPopović, NatašA (57214680239)NatašA (57214680239)PopovićDelić, Dragan (55886413300)Dragan (55886413300)DelićŠvirtlih, Neda Stojković (6603664119)Neda Stojković (6603664119)Švirtlih2025-06-122025-06-122014https://doi.org/10.2298/SARH1410564Mhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84919816893&doi=10.2298%2fSARH1410564M&partnerID=40&md5=d96b4d6064bfc4d5d8629871db8ed417https://remedy.med.bg.ac.rs/handle/123456789/8662Results Eighty percent of patients were male of average age 29.6±8.6 years; in 61.8% patients intravenous drug abuse was determined as risk factor. Thirty patients (54.1%) had no symptoms and 38.2% were icteric. Acute hepatitis C spontaneously resolved in 33.3% patients, while in the treated group 79.6% of patients completely recovered (p=0.006). Treatment success was 92.9% in the group of patients who started with treatment before the 45th day of disease, while in the patients who started treatment later the success rated 58.3% (p=0.037).; Methods Total of 55 patients with acute hepatitis C, hospitalized at the Clinic for Infectious Diseases in Belgrade from January 2005 to December 2012 were enrolled in this study. Forty-one patients were under follow-up over six months for evaluation of the development of the disease into a chronic infection and effectiveness of treatment with INF-α.; Conclusion Acute hepatitis C is most common in young male adults infected via injection drug abuse. The use of INF-α is effective in the treatment of the disease, and success of the treatment is more probable if treatment is started before the 45th day.; Introduction Acute hepatitis C most frequently develops after parenteral infection of hepatitis C virus. The disease often develops into chronic infection, although it can resolve spontaneously. Interferon alpha (INF-α) is used in therapy, but still without precise treatment recommendations.; Objective The aim was to present characteristics of patients with acute hepatitis C and to assess effectiveness of using re-combinant INF-α in therapy. © 2014, Srpsko Lekarsko Drutsvo. All rights reserved.Acute hepatitis CIn-terferon alphaPrognostic factorsTherapy